Cancer Therapeutics’ first product achieves preclinical proof of concept
cancer Therapeutics announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.
CTX-0294945 is a highly-selective small molecule inhibitor of focal adhesion kinase (FAK), a non-receptor tyrosine kinase implicated in solid tumour maintenance and progression. It is also an appropriate candidate for combination therapy in a range of cancers. In the present study, CTX-0294945 was combined with the anti-angiogenic antibody Avastin in an in vivo orthoptic model of triple negative breast cancer. Avastin is widely used in the clinic but its efficacy can be limited and efficacy can be short-lived. CTX-0294945 significantly augmented the effectiveness of Avastin in limiting tumour growth and also significantly increased the duration of response. CTX-0294945 also appears to inhibit tumour revascularisation and macrophage infiltration even after Avastin therapy has stopped.
Other news from the department research and development
